Hello, I am Dr. Hidenori Shimada of Grand Green Osaka Umekita Clinic in Osaka, Japan.
Regenerative medicine offers promising avenues for supporting the body’s natural healing processes. At the heart of many of these therapies are mesenchymal stem cells (MSCs), remarkable cells with the ability to influence tissue repair and inflammation. These cells can be harvested from several places in the body, but the two most common sources are bone marrow and adipose (fat) tissue. This raises an important question for anyone considering this therapy: which source is more suitable? This article explores the differences between the two and explains why, at Grand Green Osaka Umekita Clinic, we utilize adipose tissue for our stem cell therapies.
Why Adipose Tissue is a Preferred Source for Stem Cells
While both bone marrow and adipose tissue are valid sources of MSCs, the clinical choice is often guided by two primary factors: the potential therapeutic benefit and the patient’s comfort and safety. We find that adipose tissue offers a favorable balance of these factors. It is generally considered to contain a higher concentration of MSCs compared to bone marrow, and the collection process is significantly less invasive. This patient-centered approach allows for obtaining a substantial supply of viable cells while minimizing discomfort and recovery time for the individual undergoing treatment.
Common Questions When Choosing a Stem Cell Source
Patients exploring regenerative medicine often have similar concerns. They want to understand the science but are also focused on the practical aspects of the treatment. Common questions include:
- What is the difference in the number of stem cells obtainable from each source?
- How invasive is the collection procedure for fat versus bone marrow?
- What does the recovery process look like for each method?
- Are there age-related factors that affect the quality or quantity of cells from either source?
These are all critical questions. Understanding the fundamental differences between adipose and bone marrow-derived stem cells can help you have a more informed discussion with your physician and make a decision that aligns with your health goals.
The Science of Mesenchymal Stem Cells (MSCs)
Mesenchymal stem cells are adult stem cells found in various tissues. They are not the same as embryonic stem cells. Their therapeutic potential is believed to stem from several key abilities. Firstly, they can differentiate into various cell types, such as bone, cartilage, and fat cells. Secondly, and perhaps more importantly for systemic therapies, they exert powerful paracrine effects. This means they secrete a wide range of bioactive molecules—including growth factors and anti-inflammatory signals—that can help calm inflammation, modulate immune responses, and support the repair of damaged tissues. This secretome, or the collection of molecules released by MSCs, is a major focus of current research and is thought to be a primary mechanism behind their therapeutic action.
A Comparison: Adipose Tissue vs. Bone Marrow
When evaluating a suitable source for MSCs, we consider cell quantity, collection procedure, and patient impact.
Adipose (Fat) Tissue
- Cell Abundance: Adipose tissue is one of the most abundant sources of MSCs in the body. Studies have shown that, per gram of tissue, fat can yield a significantly higher number of MSCs than bone marrow. This abundance means a sufficient number of cells for potential therapeutic use can be obtained from a very small amount of tissue.
- Collection Procedure: The collection is a minor procedure performed under local anesthesia. A small incision is made, typically in the abdominal or thigh area, and a few rice-grain-sized pieces of fat are collected. The process is quick, generally well-tolerated, and performed on an outpatient basis.
- Patient Impact: The minimally invasive nature of the collection leads to less discomfort, a lower risk of complications, and a faster recovery time for the patient.
Bone Marrow
- Cell Abundance: While bone marrow has been a traditional source for stem cells, the concentration of MSCs within it is relatively low and is known to decline significantly with age. This can make it challenging to obtain a sufficient number of cells, especially from older patients.
- Collection Procedure: Bone marrow aspiration involves inserting a long needle into a bone, typically the iliac crest (hip bone), to draw out the marrow. This procedure is more invasive and can be painful.
- Patient Impact: The procedure carries a higher risk of pain, bleeding, and infection at the aspiration site. The recovery period is generally longer and more uncomfortable compared to fat tissue collection.
What to Consider Before Your Consultation in Osaka
Choosing to undergo regenerative therapy is a significant decision. It’s important to approach it with a clear understanding of what the treatment involves. At Grand Green Osaka Umekita Clinic, we ensure every patient has a thorough consultation to determine if they are a suitable candidate.
It is crucial to understand that this treatment is not a guaranteed cure for any condition, and individual results can vary. The efficacy and safety of stem cell therapy are still the subject of ongoing research worldwide. This therapy is provided as a private medical service, meaning it is not covered by Japanese public health insurance. All aspects of the treatment, including the expected outcomes, potential risks, side effects, and total costs, will be explained in detail by a physician during your consultation.
In Japan, regenerative therapies like this are strictly regulated under the Act on the Safety of Regenerative Medicine. Our treatments are provided in compliance with a plan that has been submitted to and accepted by the Ministry of Health, Labour and Welfare, ensuring a high standard of safety and quality control.
For more detailed information on our Adipose-Derived Stem Cell Therapy, including the treatment flow, fees, and potential risks, we encourage you to review our dedicated treatment page.
Summary: A Patient-First Approach to Regenerative Therapy
In the comparison of adipose vs. bone marrow as a mesenchymal stem cell source, the evidence suggests that adipose tissue is a noteworthy option for both cell quantity and patient experience. The ability to harvest a high number of MSCs through a minimally invasive outpatient procedure makes it a suitable choice for modern regenerative medicine. This aligns with our commitment at Grand Green Osaka Umekita Clinic to provide advanced therapies that prioritize patient safety and comfort.
If you are in the Osaka area of Japan and wish to learn more about adipose-derived stem cell options, we invite you to schedule a consultation. Our team is ready to provide you with the information you need to make an informed decision about your long-term health.
Adipose Tissue
- High cell concentration
- Minimally invasive collection
- Less patient impact, faster recovery
Bone Marrow
- Lower cell concentration (declines with age)
- More invasive and painful collection
- Greater patient impact, longer recovery
This is a conceptual diagram summarizing the main points of the article
References
- PubMed: Mesenchymal Stem Cell Secretome: Toward Cell-Free Therapeutic Strategies in Regenerative Medicine. (2017)
- PubMed: Single-cell transcriptome atlas of human mesenchymal stem cells exploring cellular heterogeneity. (2021)
- PubMed: Multilineage cells from human adipose tissue: implications for cell-based therapies. (2001)
- PubMed: Extracellular vesicle activities regulating macrophage- and tissue-mediated injury and repair responses. (2021)
- PubMed: Mesenchymal stem cell-derived extracellular vesicles for immunomodulation and regeneration: a next generation therapeutic tool? (2022)
- MHLW (Japan): Regenerative Medicine — Ministry of Health, Labour and Welfare, Japan
Supervising Physician
Director, Medical Corporation Shimada Clinic
Head of Clinical Practice, Grand Green Osaka Umekita Clinic
Hidenori Shimada
Graduated from the University of Tokushima Faculty of Medicine in 2005. After his initial residency, he obtained U.S. medical certification (ECFMG) and trained as a sub-intern in general surgery at the University of Washington. After completing the doctoral program at Kyoto University Graduate School of Medicine and working as a researcher at the Center for iPS Cell Research and Application (CiRA), Kyoto University, he founded Shimada Clinic in 2013. At Grand Green Osaka Umekita Clinic (https://umekitaclinic.org), he is engaged in a wide range of care, from internal medicine and pediatrics to cell therapy and aesthetic medicine.
* The physician supervision of this article covers its academic content only and does not constitute a recommendation of any specific treatment or product.